Lossos, I. S., Reis, I. M., Rosenblatt, J. D., & Alderuccio, J. P. (2020). Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma. Leukemia & lymphoma, 61(13), 3234-3238. https://doi.org/10.1080/10428194.2020.1802449
Chicago-Zitierstil (17. Ausg.)Lossos, Izidore S., Isildinha M. Reis, Joseph D. Rosenblatt, und Juan Pablo Alderuccio. "Long-term Outcomes of Frontline 90Y-ibritumomab Tiuxetan in Marginal Zone Lymphoma." Leukemia & Lymphoma 61, no. 13 (2020): 3234-3238. https://doi.org/10.1080/10428194.2020.1802449.
MLA-Zitierstil (9. Ausg.)Lossos, Izidore S., et al. "Long-term Outcomes of Frontline 90Y-ibritumomab Tiuxetan in Marginal Zone Lymphoma." Leukemia & Lymphoma, vol. 61, no. 13, 2020, pp. 3234-3238, https://doi.org/10.1080/10428194.2020.1802449.